Inhibition of a new AXL isoform, AXL3, induces apoptosis of mantle cell lymphoma cells
Blood · 2023
DOI: 10.1182/blood.2022015581 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, 2023. Verfasst von Pascal Gelebart und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Science, University of Bergen, Bergen, Norway. Hauptthemen laut MEDLINE: Protein-Tyrosine Kinases, Lymphoma, Mantle-Cell. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma having a poor overall survival that is in need for the development of new therapeutics. In this study, we report the identification and expression of a new isoform splice variant of the tyrosine kinase receptor AXL in MCL cells. This new AXL isoform, called AXL3, lacks the ligand-binding domain of the commonly described AXL splice variants and is constitutively activated in MCL cells. Interestingly, functional characterization of AXL3, using CRISPR inhibition, revealed that only the knock down of this isoform leads to apoptosis of MCL cells. Importantly, pharmacological inhibition of AXL activity resulted in a significant decrease in the activation of well-known proproliferative and survival pathways activated in MCL cells (ie, β-catenin, Ak strain transforming, and NF-κB). Therapeutically, preclinical studies using a xenograft mouse model of MCL indicated that bemcentinib is more effective than ibrutinib in reducing the tumor burden and to increase the overall survival. Our study highlights the importance of a previously unidentified AXL splice variant in cancer and the potential of bemcentinib as a targeted therapy for MCL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Science, University of Bergen, Bergen, Norway.
- Department of Hematology, Haukeland University Hospital, Bergen, Norway.
- Department of Pathology, Haukeland University Hospital, Bergen, Norway.
- INSERM, UMR U976, Institut Saint-Louis, Paris, France.
- Institut de Recherche Saint-Louis, Hôpital Saint-Louis, Paris, France.
- INSERM U978, University of Paris 13, Bobigny, France.
ORCID-Profile: Pascal Gelebart, May Eriksen Gjerstad, Jianhua Han, Bela Papp, Fanny Baran-Marszak, Emmet McCormack
Zitieren
APA
Gelebart, P., Eriksen Gjerstad, M., Benjaminsen, S., Han, J., Karlsen, I., Safont, M. M., Leitch, C., Fandalyuk, Z., Popa, M., Helgeland, L., Papp, B., Baran-Marszak, F., & McCormack, E. (2023). Inhibition of a new AXL isoform, AXL3, induces apoptosis of mantle cell lymphoma cells. Blood. https://doi.org/10.1182/blood.2022015581
Vancouver
Gelebart P, Eriksen Gjerstad M, Benjaminsen S, Han J, Karlsen I, Safont MM, et al. Inhibition of a new AXL isoform, AXL3, induces apoptosis of mantle cell lymphoma cells. Blood. 2023. doi:10.1182/blood.2022015581
BibTeX
@article{Gelebart2023,
author = {Gelebart, Pascal and Eriksen Gjerstad, May and Benjaminsen, Susanne and Han, Jianhua and Karlsen, Ida and Safont, Mireia Mayoral and Leitch, Calum and Fandalyuk, Zinayida and Popa, Mihaela and Helgeland, Lars and Papp, Bela and Baran-Marszak, Fanny and McCormack, Emmet},
title = {Inhibition of a new AXL isoform, AXL3, induces apoptosis of mantle cell lymphoma cells},
journal = {Blood},
year = {2023},
doi = {10.1182/blood.2022015581}
}
EUVIMED